Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the safety and effectiveness of micafungin in combination with AmBisome as first-line therapy in the treatment of invasive aspergillosis.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Astellas Pharma Inc
NCT03748069 · Influenza With Pneumonia, Invasive Pulmonary Aspergillosis
NCT06244979 · Pulmonary Aspergillosis, Chronic Pulmonary Aspergillosis, and more
NCT06537726 · Leukemia, Leukemia, Myeloid, and more
NCT03717623 · Posaconazole, Pharmacokinetics, and more
NCT06440915 · Aspergillosis Invasive, Mucormycosis
Washington D.C., District of Columbia
Atlanta, Georgia
Ann Arbor, Michigan
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions